The
Gilead, which sells remdesivir under the brand name Veklury, issued a statement saying it was the first drug to be approved to treat COVID-19 patients that require hospitalization after previously being authorized by the FDA for emergency use.
"As an antiviral drug, Veklury works to stop replication of SARS-CoV-2, the virus that causes COVID-19," the company said.
Veklury was approved for treatment of adults and pediatric patients aged 12 or older and weighing at least 88 pounds and "should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care," Gilead said.
The company added that the approval was based on three randomized controlled trials including final results of a double-blind, placebo-controlled trial by the
President
A study by the
Copyright 2020 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source